Shares of HLS Therapeutics Inc. (OTCMKTS:HLTRF – Get Free Report) traded up 3% on Friday . The stock traded as high as $3.09 and last traded at $3.09. Approximately 100 shares traded hands during mid-day trading, a decline of 87% from the average daily volume of 784 shares. The stock had previously closed at $3.00.
HLS Therapeutics Stock Performance
The stock has a 50-day moving average price of $3.21 and a 200-day moving average price of $3.28.
HLS Therapeutics Company Profile
HLS Therapeutics is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription products for niche therapeutic markets. Headquartered in Mississauga, Ontario, the company builds its portfolio through strategic licensing agreements and in-house development, with an emphasis on therapies that address unmet needs in neurology and rare disorders.
The company’s marketed offering includes treatments for neurological conditions, most notably primary periodic paralysis, for which it commercializes dichlorphenamide (Keveyis) in North America.
Featured Stories
- Five stocks we like better than HLS Therapeutics
- AeroVironment Flies Under Wall Street’s Radar Toward a $4 Billion Target
- Micron’s $250 Billion Bet Could Reshape the AI Memory Race
- Rocket Lab’s Stock Drop Comes With a Bullish Twist
- Amazon’s New Debt Deal Puts Its AI Spending Story on Trial
Receive News & Ratings for HLS Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HLS Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
